frontiers | Frontiers in Cellular and Infection Microbiology

TYPE Correction
PUBLISHED 14 February 2023
DOI 10.3389/fcimb.2022.1075768

OPEN ACCESS

EDITED AND REVIEWED BY
Rey Carabeo,
University of Nebraska Medical Center,
United States

*CORRESPONDENCE
Jennifer H. Shaw
jennifer.h.shaw@okstate.edu
Erika I. Lutter
erika.lutter@okstate.edu

SPECIALTY SECTION
This article was submitted to Bacteria and Host, a section of the journal Frontiers in Cellular and Infection Microbiology

RECEIVED 20 October 2022
ACCEPTED 25 October 2022
PUBLISHED 14 February 2023

CITATION
Shaw JH, Key CE, Snider TA, Sah P, Shaw EI, Fisher DJ and Lutter EI (2023) Corrigendum: Genetic inactivation of *Chlamydia trachomatis* inclusion membrane protein CT228 alters MYPT1 recruitment, extrusion production, and longevity of infection. *Front. Cell. Infect. Microbiol.* 12:1075768. doi: 10.3389/fcimb.2022.1075768

Corrigendum: Genetic inactivation of *Chlamydia trachomatis* inclusion membrane protein CT228 alters MYPT1 recruitment, extrusion production, and longevity of infection

Jennifer H. Shaw[1]*, Charlotte E. Key[1], Timothy A. Snider[2], Prakash Sah[3], Edward I. Shaw[3], Derek J. Fisher[4] and Erika I. Lutter[3]*

[1]Department of Integrative Biology, Oklahoma State University, Stillwater, OK, United States, [2]Department of Veterinary Pathobiology, Oklahoma State University, Stillwater, OK, United States, [3]Department of Microbiology and Molecular Genetics, Oklahoma State University, Stillwater, OK, United States, [4]Department of Microbiology, Southern Illinois University, Carbondale, IL, United States

KEYWORDS

***Chlamydia*, extrusion, lymphogranuloma venereum, L2 serovar, sexually transmitted infection, urogenital infection, CT228, mouse infection**

A Corrigendum on:

Genetic inactivation of Chlamydia trachomatis inclusion membrane protein CT228 Alters MYPT1 recruitment, extrusion production, and longevity of infection.

By Shaw JH, Key CE, Snider TA, Sah P, Shaw EI, Fisher DJ and Lutter EI (2018) *Front. Cell. Infect. Microbiol.* 8:415. doi: 10.3389/fcimb.2018.00415

Error in Figures/Table

In the published article, there was an error in Figure 3A; panel MLC2 as published: Images for MLCK were duplicated in place of MLC2. The corrected Figure 3A; panel for MLC2 and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.



FIGURE 3
Recruitment of MYPT1 and Myosin phosphatase pathway components and extrusion production by C. trachomatis L2-wild type and L2-1CT228. HeLa cell monolayers were infected at a MOI of ~0.5 with L2-wild type and L2-1CT228 for 18 h (in technical triplicate). Cells were fixed and stained with primary antibodies to MYPT1, Chlamydia LPS, MLC2 (pS19), Src Y474, MLCK (pY471), non-muscle Myosin IIa and IIb followed by fluorescent secondary antibodies. Experiments were repeated on three separate occasions and representative images were selected. **(A, B)** Top panel shows individual and merged images of MYPT1 recruitment (green) and Chlamydia LPS staining (red) in both the L2-wild type and L2-1CT228. Lower panel of individual and merged images show MLC2 (pS19), MLCK (pY471), and Mysoin IIa and IIb (green) co-localizing with active Src Y474 kinase (red) in microdomains at the periphery of inclusions in both L2-wild type and L2-1CT228. Scale bar, 10μm. **(C)** Total protein from L2-wild type and L2-1CT228 infected HeLa cells at 24 and 48 h post-infection were assessed for MLC2, MLC2 (pS19), HsP60, and GAPDH levels by western blot analysis. **(D)** HeLa cells were treated with either Scramble (Scr) or MYPT1 siRNA for 48 h prior to infection with L2-wild type and L2-1CT228. Protein samples were assessed for MYPT1 and GAPDH levels by western blot. **(E)** Extrusions collected and **(F)** IFUs were assessed for L2 wild-type and L2-1CT228 at 48 h post-infection in either Scramble (symbols and solid bars) or MYPT1 (open symbols and white bars) siRNA treated HeLa cells. *p < 0.0001.

Publisher's note